title: Platelet hyperaggregability to platelet activating factor (PAF) in non-ST elevation acute coronary syndromes.
abstract: It is known that myocardial ischaemia increases platelet aggregatory response to various agonists, ex vivo. We investigated the platelet aggregatory response to platelet activating factor (PAF), ex vivo, in patients with non-ST elevation acute coronary syndromes and determined the specificity and sensitivity of this response. Thirty-two consecutive patients with non-ST elevation acute coronary syndromes and 20 healthy volunteers were studied. Platelet aggregation in platelet-rich plasma was studied on the day of admission. The maximal aggregation achieved within 2 min after the addition of PAF (100 nM) was expressed as a percentage of 100% light transmission. PAF EC50 values were defined as the concentration that induces 50% of maximal aggregation. The PAF EC50 values of the non-ST elevation acute coronary syndromes patients were significantly lower compared to those of the controls (p < 0.0001). The maximal percentage of aggregation was also significantly higher (p < 0.0005). Ninety-one per cent of the patients were correctly classified using PAF EC50 values (specificity 90.0% and sensitivity 91.2%); the corresponding results using the maximal percentage of aggregation were 80% (specificity 70.0% and sensitivity 87.5%). The estimated values used as thresholds were 22.47 nM and 17.97 for the PAF EC50 and the maximal percentage of aggregation, respectively. The results of the present study suggest that platelet hyperaggregability to PAF, ex vivo, in non-ST elevation acute coronary syndromes is characterised by a high specificity and sensitivity, and thus it may represent a mechanism contributing to the pathophysiology of acute coronary syndromes.
authors.affiliation: Department of Cardiology, University Hospital of Ioannina, Greece. lmihalis@cc.uoi.gr
authors.forename: L K
authors.initials: LK
authors.lastname: Michalis
authors.forename: A P
authors.initials: AP
authors.lastname: Tambaki
authors.forename: C S
authors.initials: CS
authors.lastname: Katsouras
authors.forename: J A
authors.initials: JA
authors.lastname: Goudevenos
authors.forename: T
authors.initials: T
authors.lastname: Kolettis
authors.forename: K
authors.initials: K
authors.lastname: Adamides
authors.forename: A D
authors.initials: AD
authors.lastname: Tselepis
authors.forename: D A
authors.initials: DA
authors.lastname: Sideris
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D016022:Case-Control Studies; D003327:Coronary Disease / Q000097:blood*; D004562:Electrocardiography; D005260:Female; D006801:Humans; D066298:In Vitro Techniques; D008297:Male; D008875:Middle Aged; D010972:Platelet Activating Factor / Q000494:pharmacology*; D010974:Platelet Aggregation / Q000187:drug effects*; D012680:Sensitivity and Specificity; D013577:Syndrome
chemical_list: D010972:Platelet Activating Factor